National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

News

Contact the NCI Office of Media Relations | RSS Feed

    Posted: 10/09/2009
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Find News Releases

  Search For:  
   
  Between these dates:

 
      
      
spacer image
  Search          
BenchMarks
BenchMarks

   
Modeling Different Breast Cancer Screening Strategies

Media Resources
Noticias

Understanding Cancer Series

Visuals Online
An NCI database of cancer-specific scientific and patient care-related images, as well as general biomedical and science-related images and portraits of NCI directors and staff.

Video PressPacks
[The NewsMarket]

Video Asset Library
[The NewsMarket]

B-Roll Footage

Radio Broadcasts

Entertainment Resources
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

caBIG: Connecting the Cancer Community
News Note: Gene Therapy Method Slows Tumor Growth in Mice

NCI researchers have developed a novel method in mice of delivering genes to cancer cells, that when expressed, promote cell death. These genes, known as suicide genes, cause a cell to kill itself through a process known as apoptosis. The new technique uses the survivin gene promoter to express the suicide gene and induce apoptosis in cancer cells. This method of gene delivery effectively targeted tumor cells with a minimum effect on normal cells.

Tumor specific promoters, such as the survivin promoter, can be used to target genes to cancer cells, but the expression of the protein product is often suboptimal. The NCI team devised a way to overcome this problem by developing a more potent suicide gene. They created a mutation in the area of the suicide gene bax that regulates its apoptotic activity. Laboratory studies showed that when expressed via the survivin promoter, the mutant bax gene had increased cell killing activity in a variety of cancer cell types compared to the unmutated form of the gene. The researchers also found that the survivin promoter-driven mutant bax was minimally toxic to normal human skin cells. When injected into tumors of mice, the gene induced more than 60 percent of the cancer cells in the tumor tissue to die and slowed tumor growth significantly. The results of this study appeared online October 9, 2009, in Cancer Gene Therapy.

Back to TopBack to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov